On March 8, 2022 ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, reported that it will present preclinical data for its first generation of androgen receptor (AR) N-terminal domain degraders at the 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, ESSA, MAR 8, 2022, View Source [SID1234609729]). The ANITen bAsed Chimera (ANITAC) degraders suppressed AR transcriptional activity and decreased the viability of prostate cancer cells in castration-resistant prostate cancer (CRPC) preclinical models. ANITAC degraders degraded full length, mutant and splice variant forms of AR that are expressed in CRPC patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster presentation details are as follows:

Title: Androgen receptor (AR) N-Terminal Domain degraders can degrade AR full length and AR splice variants in CRPC preclinical models
Authors: Nan Hyung Hong, et al.
Abstract Number: 429
Session Title: Protein Degraders and Proteasome Inhibitors
Session Date and Time: Sunday, April 10, 2022 | 1:30 p.m. – 5:00 p.m. ET
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 26

The e-poster will be available to 2022 AACR (Free AACR Whitepaper) Annual Meeting attendees and on the Company’s website at www.essapharma.com on April 8, 2022, at 1:00 p.m. ET.